Weiss Ratings Reiterates Sell (D-) Rating for Caribou Biosciences (NASDAQ:CRBU)

Key Points

• Weiss Ratings has reiterated a sell (D-) rating for Caribou Biosciences (NASDAQ: CRBU), indicating concerns about the company's performance.
• Despite the sell rating from Weiss, Wall Street Zen upgraded Caribou Biosciences from a "sell" to a "hold," suggesting mixed perceptions among analysts.
• The stock has a market cap of $249.56 million and has experienced significant trading volume, with shares recently increasing to $2.68.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report)'s stock had its "sell (d-)" rating reiterated by investment analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded Caribou Biosciences from a "sell" rating to a "hold" rating in a report on Sunday, August 24th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $6.67.

Caribou Biosciences Price Performance

Shares of NASDAQ:CRBU traded up $0.25 during mid-day trading on Wednesday, reaching $2.68. 2,697,922 shares of the company traded hands, compared to its average volume of 1,289,615. Caribou Biosciences has a 52 week low of $0.66 and a 52 week high of $3.00. The firm has a market cap of $249.56 million, a PE ratio of -1.51 and a beta of 2.59. The company's 50 day moving average price is $1.95 and its 200-day moving average price is $1.44.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.05. Caribou Biosciences had a negative return on equity of 62.35% and a negative net margin of 1,800.93%.The business had revenue of $2.67 million for the quarter, compared to analysts' expectations of $1.64 million. On average, research analysts predict that Caribou Biosciences will post -1.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Caribou Biosciences

Institutional investors have recently added to or reduced their stakes in the stock. Jacobs Levy Equity Management Inc. raised its stake in Caribou Biosciences by 19.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,442,121 shares of the company's stock valued at $1,317,000 after buying an additional 234,052 shares during the last quarter. Aberdeen Group plc raised its position in Caribou Biosciences by 118.3% in the second quarter. Aberdeen Group plc now owns 897,579 shares of the company's stock valued at $1,131,000 after purchasing an additional 486,435 shares during the period. Pale Fire Capital SE grew its stake in shares of Caribou Biosciences by 7.2% in the first quarter. Pale Fire Capital SE now owns 786,722 shares of the company's stock valued at $718,000 after buying an additional 52,518 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in Caribou Biosciences during the 1st quarter worth $559,000. Finally, AQR Capital Management LLC boosted its position in shares of Caribou Biosciences by 741.6% during the 1st quarter. AQR Capital Management LLC now owns 525,878 shares of the company's stock worth $480,000 after acquiring an additional 463,391 shares in the last quarter. Institutional investors own 77.51% of the company's stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.